Searched for
METABOLIC THERAPY
'Cheaper than a gym, but still not selling': Nithin Kamath on why Indians aren't embracing popular weight-loss drugsDespite rising obesity and affordable generic GLP-1 drugs, India lags in adoption. Nithin Kamath highlights patient retention challenges wi...- AIIMS doctors say yoga could be one of the most powerful tools for women’s health: 5 important reasons every woman should practise it every dayYoga is emerging as an important tool in managing polyendocrine metabolic ovarian syndrome (PMOS), formerly known as PCOS. Experts say that...
- Your brain may activate a powerful muscle-building, fat-burning switch while you are in deep sleep. New research stuns scientistsNew research has revealed that deep sleep isn't just for rest; it actively regulates growth hormone, crucial for muscle repair, bone streng...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- The hidden cost of looking better: What health insurance covers, and what it leaves you to payRising demand for weight-loss drugs, cosmetic procedures and wellness treatments is creating a growing out-of-pocket healthcare expense cat...
- Over 1,500 bat species carry thousands of deadly viruses but rarely get sick, and scientists are only just beginning to understand whyBats possess a unique, preactivated innate immune defense that stops viruses from fully replicating, even after cell entry. This remarkable...
- In 1889, a physician noticed a sweet urine clue and helped point medicine toward insulinIn a groundbreaking moment in 1889, two German scientists, Joseph von Mering and Oskar Minkowski, uncovered a crucial link between the panc...
- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Margin pressure, slower growth outlook may cap upside for Sun Pharma stockSun Pharma reported strong revenue and profit growth in the March quarter, but EBITDA margins faced pressure from increased investments and...
- Eli Lilly brings monthly Alzheimer's therapy donanemab to India at ₹91,688 per vialEli Lilly is making Alzheimer's a major focus for its future innovations. The company is also expanding its specialty medicine offerings in...
- Alzheimer's a key part of Eli Lilly's India specialty medicine push, says company's country head Winselow TuckerEli Lilly has introduced Lormalzi in India, a pioneering treatment for Alzheimer's that specifically targets amyloid plaques, a significant...
- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- Dr Reddy's and Nestle Health Science strengthen presence in diabetes, obesity nutrition spaceDr Reddy's teams up with Nestle Health Science to introduce Celevida GLP+, a specialized supplement crafted for those navigating the challe...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Social media is abuzz with weight-loss drug retatrutide and longevity goals. What is the drug all about?A new weight-loss drug, retatrutide, is generating excitement. This investigational medicine targets three hormone receptors, offering a po...
- Ajanta Pharma, Sun Pharma poised to tap GLP-1 opportunity amid market shift: Siddhartha KhemkaIndia's metabolic therapy market is transforming post-semaglutide patent expiry, shifting to a competitive, volume-driven model. With signi...
- Semaglutide patent expiry: India’s next big public health inflection pointThe expiry of a key patent for semaglutide in India opens doors for affordable weight-loss and diabetes drugs. Indian pharmaceutical compan...
- Natco Pharma, Eris Lifesciences shares jump up to 6% on partnership for Semaglutide launch in IndiaShares of Natco Pharma and Eris Lifesciences climbed on Tuesday after announcing a partnership to commercialise Semaglutide in India. Natco...
Load More
